Last reviewed · How we verify
chemoradiotherapy Cisplatin
chemoradiotherapy Cisplatin is a Platinum-based chemotherapy Small molecule drug developed by Shandong Cancer Hospital and Institute. It is currently in Phase 3 development for Non-small cell lung cancer, ovarian cancer, testicular cancer, bladder cancer, and other types of cancer, Head and neck cancer. Also known as: Cisplatin.
Cisplatin works by interfering with DNA replication, causing cell death in rapidly dividing cancer cells.
Cisplatin is a small molecule used in chemoradiotherapy, specifically in the treatment of locally advanced cervical carcinoma and gastric cancer. It is administered concurrently with radiotherapy and other chemotherapeutic agents, such as albumin-bound paclitaxel, as part of a treatment regimen.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | chemoradiotherapy Cisplatin |
|---|---|
| Also known as | Cisplatin |
| Sponsor | Shandong Cancer Hospital and Institute |
| Drug class | Platinum-based chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cisplatin is a platinum-based chemotherapy drug that forms platinum-DNA adducts, which trigger DNA repair mechanisms and ultimately lead to cell death. This process is particularly effective in rapidly dividing cancer cells, making cisplatin an effective treatment for various types of cancer.
Approved indications
- Non-small cell lung cancer, ovarian cancer, testicular cancer, bladder cancer, and other types of cancer
- Head and neck cancer
Common side effects
- Nausea and vomiting
- Neutropenia
- Anemia
- Thrombocytopenia
- Kidney damage
Key clinical trials
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
- Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer (PHASE1)
- Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer (PHASE3)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma (PHASE2)
- Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer (PHASE3)
- Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) (PHASE3)
- A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esophageal Cancer Based on Dynamic ctDNA Monitoring (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- chemoradiotherapy Cisplatin CI brief — competitive landscape report
- chemoradiotherapy Cisplatin updates RSS · CI watch RSS
- Shandong Cancer Hospital and Institute portfolio CI
Frequently asked questions about chemoradiotherapy Cisplatin
What is chemoradiotherapy Cisplatin?
How does chemoradiotherapy Cisplatin work?
What is chemoradiotherapy Cisplatin used for?
Who makes chemoradiotherapy Cisplatin?
Is chemoradiotherapy Cisplatin also known as anything else?
What drug class is chemoradiotherapy Cisplatin in?
What development phase is chemoradiotherapy Cisplatin in?
What are the side effects of chemoradiotherapy Cisplatin?
Related
- Drug class: All Platinum-based chemotherapy drugs
- Manufacturer: Shandong Cancer Hospital and Institute — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer, ovarian cancer, testicular cancer, bladder cancer, and other types of cancer
- Indication: Drugs for Head and neck cancer
- Also known as: Cisplatin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing